Podcast

Podcast: This Week in Managed Care - Gottlieb Passes Committee, and Other News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

Last week, President Donald Trump's nominee for FDA was confirmed by a Senate committee and will now go before the full Senate for a vote; community oncologists met to discuss the Cancer Moonshot and the trouble with pharmacy benefit managers; and a study found obesity shortens more lives than cigarettes.

Listen below or through one of these podcast services:

iTunes: http://apple.co/2eYWTss

TuneIn: http://bit.ly/2gv7iwj

Stitcher: http://bit.ly/2gCqtFg

Related Videos
John Buse, MD, PhD
Marc P. Bonaca, MD, MPH
Cathy Eng, MD, FACP, FASCO
Jorge García, PharmD, MS, MBA, MHA, FACHE, FACCC
Screenshot of an interview with Shaun McKenzie, MD
Screenshot of an interview with Shaun McKenzie, MD
Screenshot of an interview with Rohan Garje, MD
Susan Escudier, MD, FACP
Sabarish Ayyappan, MD
Related Content
Round FDA approval stamp in blue ink | Image Credit: © Surendra - stock.adobe.com
March 31st 2025

FDA Approves Durvalumab Combo for Muscle-Invasive Bladder Cancer

Maggie L. Shaw
The approval follows the December 2024 priority review designation for this perioperative immunotherapy regimen for patients fighting muscle-invasive bladder cancer.
Managed Care Cast Logo
February 25th 2025

Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care

Pearl Steinzor Arthur L. Jenkins III, MD, FACS
On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
FDA Approved. | Image Credit: wladimir1804 - stock.adobe.com
March 26th 2025

FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors

Giuliana Grossi
With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.
managed care cast logo
February 18th 2025

Varied Access: The Pharmacogenetic Testing Coverage Divide

Brooke McCormick Jai N. Patel, PharmD
On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Doctor showing patient x-ray of lung cancer. | Image credit: Nattakorn – stock.adobe.com
March 25th 2025

3 DDR Phenotypes May Predict Chemotherapy Response in SCLC

Hayden E. Klein
One study showed small cell lung cancer (SCLC) tumors with higher DNA damage response (DDR) activity were initially more sensitive to chemotherapy but had worse overall survival.
Estrogen | Image credit: Debalina - stock.adobe.com
March 20th 2025

Estrogen Therapy May Increase Risk of 3 Skin Cancers

Hayden E. Klein
Researchers of a Swedish study advise physicians to consult with their patients about these risks and take extra precautions, but did not recommend discontinuation of any of the drugs studied.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo